FDA Clearance Tracker · P130007-S016
OneTouch Vibe Plus System
Last checked: Nov 20, 2026Latest source record: Dec 16, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Dec 16, 2016
Approved
Time to decision
193 days
Received Jun 6, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P130007-S016
- Device name
- OneTouch Vibe Plus System
- Applicant
- Animas Corp.
- Applicant location
- Wayne, PA
- Received
- Jun 6, 2016
- Decided
- Dec 16, 2016
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P130007
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the OneTouch Vibe Plus System is indicated for continuous subcutaneous insulin infusion for the management of insulin-requiring diabetes. It can be used solely for continuous insulin delivery and as part of the OneTouch Vibe Plus System to receive and display continuous glucose measurements from the Dexcom G5® Sensor and Transmitter. The OneTouch Vibe Plus System's continuous glucose monitoring (CGM) is indicated for detecting trends and tracking patterns in persons (ages 2 and older) with diabetes, and is intended to complement, not replace, information obtained from standard home glucose monitoring devices. CGM aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimize these excursions. Interpretation of results from the Dexcom G5® Sensor and Transmitter should be based on the trends and patterns seen with several sequential readings over time. The System is intended for single patient use and requires a prescription.The Animas® Vibe® Systems continuous glucose monitoring (CGM) is indicated for detecting trends and tracking patterns in persons (age 2 and older) with diabetes, and is intended to complement, not replace, information obtained from standard home glucose monitoring devices. CGM aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimize these excursions. Interpretation of results from the Dexcom G5® Sensor and Transmitter should be based on the trends and patterns seen with several sequential readings over time.The System is intended for single patient use and requires a prescription.
Source documents
Other decisions for Animas Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- ANIMAS VIBE SYSTEMPMA supplement
P130007-S004 · Decided Dec 24, 2015 · 238 days after receipt · Panel Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.